These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 12458332

  • 1. Usefulness of whole body positron emission tomography (PET) with 18F-fluoro-2-deoxyglucose (FDG) to detect recurrent ovarian cancer based on asymptomatically elevated serum levels of tumor marker.
    Chang WC, Hung YC, Kao CH, Yen RF, Shen YY, Lin CC.
    Neoplasma; 2002; 49(5):329-33. PubMed ID: 12458332
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C, Bissoli S, Pasquali C, Frison L, Liessi G, Chierichetti F, Pedrazzoli S.
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.
    Yen RF, Sun SS, Shen YY, Changlai SP, Kao A.
    Anticancer Res; 2001 Dec; 21(5):3691-4. PubMed ID: 11848544
    [Abstract] [Full Text] [Related]

  • 6. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
    Shen YY, Liang JA, Chen YK, Tsai CY, Kao CH.
    Hepatogastroenterology; 2006 Dec; 53(69):348-50. PubMed ID: 16795969
    [Abstract] [Full Text] [Related]

  • 7. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site.
    Pelosi E, Pennone M, Deandreis D, Douroukas A, Mancini M, Bisi G.
    Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):15-22. PubMed ID: 16557200
    [Abstract] [Full Text] [Related]

  • 8. [FDG dual-head tomography with coincidence imaging and serum tumor marker assays for the assessment of malignancy of pulmonary lesions].
    Wang HQ, Miao JS, Wu JY, Pan HZ, Shen Y, Liu JJ.
    Zhonghua Jie He He Hu Xi Za Zhi; 2003 Jan; 26(1):10-3. PubMed ID: 12775261
    [Abstract] [Full Text] [Related]

  • 9. Early detection of recurrent ovarian cancer in patients with low-level increases in serum CA-125 levels by 2-[F-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.
    Peng NJ, Liou WS, Liu RS, Hu C, Tsay DG, Liu CB.
    Cancer Biother Radiopharm; 2011 Apr; 26(2):175-81. PubMed ID: 21510748
    [Abstract] [Full Text] [Related]

  • 10. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
    Torizuka T, Nobezawa S, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, Takekuma M, Maeda M, Ouchi Y.
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Combined positron emission tomography-computed tomography and tumor markers for detecting recurrent ovarian cancer.
    Pan HS, Lee SL, Huang LW, Chen YK.
    Arch Gynecol Obstet; 2011 Feb; 283(2):335-41. PubMed ID: 20221620
    [Abstract] [Full Text] [Related]

  • 14. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
    Hefler L, Tempfer C, Häusler G, Heinzl H, Kainz C.
    Wien Klin Wochenschr; 1998 Oct 02; 110(18):635-41. PubMed ID: 9816636
    [Abstract] [Full Text] [Related]

  • 15. Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti-CEA monoclonal antibody.
    Juweid M, Sharkey RM, Alavi A, Swayne LC, Herskovic T, Hanley D, Rubin AD, Pereira M, Goldenberg DM.
    J Nucl Med; 1997 Feb 02; 38(2):257-60. PubMed ID: 9025751
    [Abstract] [Full Text] [Related]

  • 16. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels.
    Bhosale P, Peungjesada S, Wei W, Levenback CF, Schmeler K, Rohren E, Macapinlac HA, Iyer RB.
    Int J Gynecol Cancer; 2010 Aug 02; 20(6):936-44. PubMed ID: 20683399
    [Abstract] [Full Text] [Related]

  • 17. The role of FDG-PET/CT in ovarian cancer patients with high tumor markers or suspicious lesion on contrast-enhanced CT in evaluation of recurrence and/or in determination of intraabdominal metastases.
    Sari O, Kaya B, Kara PO, Gedik GK, Celik C, Ozbek O, Serdengecti M.
    Rev Esp Med Nucl Imagen Mol; 2012 Aug 02; 31(1):3-8. PubMed ID: 21549452
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting recurrent ovarian carcinoma. Initial report.
    Yuan CC, Liu RS, Wang PH, Ng HT, Yeh SH.
    J Reprod Med; 1999 Sep 02; 44(9):775-8. PubMed ID: 10509300
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.